Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type II diabetes.
J Ethnopharmacol
; 197: 61-72, 2017 Feb 02.
Article
em En
| MEDLINE
| ID: mdl-27452659
Palavras-chave
Cassia auriculata; Chrysin (PubChem CID: 5281607); Ellagic acid (PubChem CID: 5281855); Epigallocatechin gallate (PubChem CID: 65064); Immunometabolic pathway; In silico target prediction; Kaempferol 7-O-rhamnoside-4'-O-glucoside (PubChem CID: 5280863); Luteolin (PubChem CID: 5280445); Mode of action; PI3K signalling pathway; PPAR-γ; Procyanidin B2 (PubChem CID: 122738); Quercetin-3-O-ß-D-glucopyranoside (PubChem CID: 15959354); Taxifolin (PubChem CID: 439533); ± Catechin (PubChem CID: 9064), 1,2-benzenedicarboxylic acid bis(2-methylpropyl)ester (PubChem CID: 3085853/92160557)
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Extratos Vegetais
/
Cassia
/
Diabetes Mellitus Tipo 2
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
J Ethnopharmacol
Ano de publicação:
2017
Tipo de documento:
Article